VU
Valence8 US Portfolio holdings
AUM
$238M
This Quarter Return
+5.83%
1 Year Return
+14.65%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$229M
AUM Growth
+$229M
(+20%)
Cap. Flow
+$26.2M
Cap. Flow
% of AUM
11.43%
Top 10 Holdings %
Top 10 Hldgs %
96.09%
Holding
56
New
31
Increased
3
Reduced
4
Closed
–
Top Buys
| 1 |
iShares MSCI USA Quality Factor ETF
QUAL
|
$6.53M |
| 2 |
Invesco QQQ Trust
QQQ
|
$5.58M |
| 3 |
iShares MSCI Intl Quality Factor ETF
IQLT
|
$5.56M |
| 4 |
Jazz Pharmaceuticals
JAZZ
|
$999K |
| 5 |
Bristol-Myers Squibb
BMY
|
$920K |
Top Sells
| 1 |
Vanguard Value ETF
VTV
|
$589K |
| 2 |
Utilities Select Sector SPDR Fund
XLU
|
$295K |
| 3 |
iShares MSCI United Kingdom ETF
EWU
|
$284K |
| 4 |
Consumers Staples Select Sector SPDR Fund
XLP
|
$252K |
Sector Composition
| 1 | Healthcare | 4.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
iShares MSCI USA Quality Factor ETF
QUAL
$54.2B
| $60.5M | 25.1% | 337,472 +36,424 | +12% | +$6.53M |
|
|
2
Invesco QQQ Trust
QQQ
$364B
| $43M | 17.84% | 88,149 +11,438 | +15% | +$5.58M |
|
|
3
iShares MSCI Intl Quality Factor ETF
IQLT
$12.8B
| $42.6M | 17.66% | 1,026,290 +134,097 | +15% | +$5.56M |
|
4
iShares MSCI EAFE Value ETF
EFV
$27.8B
| $23M | 9.53% | 399,186 | – | – |
|
|
5
Vanguard Value ETF
VTV
$144B
| $16.9M | 7% | 96,630 -3,373 | -3% | -$589K |
|
|
6
Consumers Staples Select Sector SPDR Fund
XLP
$15.8B
| $13.7M | 5.69% | 165,267 -3,033 | -2% | -$252K |
|
|
7
iShares MSCI United Kingdom ETF
EWU
$2.9B
| $7.83M | 3.25% | 209,344 -7,590 | -3% | -$284K |
|
8
iShares MSCI Japan ETF
EWJ
$15.3B
| $7.77M | 3.22% | 108,634 | – | – |
|
|
9
Utilities Select Sector SPDR Fund
XLU
$20.9B
| $4.2M | 1.74% | 51,940 -3,648 | -7% | -$295K |
|
|
10
Jazz Pharmaceuticals
JAZZ
$7.75B
| $999K | 0.41% | +8,969 | New | +$999K |
|
|
11
Bristol-Myers Squibb
BMY
$96B
| $920K | 0.38% | +17,785 | New | +$920K |
|
12
Ascendis Pharma
ASND
$11.8B
| $685K | 0.28% | +4,585 | New | +$685K |
|
13
Insmed
INSM
$28.8B
| $574K | 0.24% | +7,865 | New | +$574K |
|
14
Indivior
INDV
$3.03B
| $564K | 0.23% | +57,293 | New | +$564K |
|
15
Eli Lilly
LLY
$657B
| $561K | 0.23% | +633 | New | +$561K |
|
16
argenx
ARGX
$43.6B
| $517K | 0.21% | +953 | New | +$517K |
|
17
Soleno Therapeutics
SLNO
$3.6B
| $490K | 0.2% | +9,706 | New | +$490K |
|
18
Keros Therapeutics
KROS
$618M
| $466K | 0.19% | +8,025 | New | +$466K |
|
19
Nuvalent
NUVL
$5.52B
| $421K | 0.17% | +4,115 | New | +$421K |
|
20
Janux Therapeutics
JANX
$1.37B
| $357K | 0.15% | +7,857 | New | +$357K |
|
21
Crinetics Pharmaceuticals
CRNX
$2.92B
| $342K | 0.14% | +6,684 | New | +$342K |
|
22
Tyra Biosciences
TYRA
$675M
| $310K | 0.13% | +13,188 | New | +$310K |
|
23
Apogee Therapeutics
APGE
$2.17B
| $308K | 0.13% | +5,240 | New | +$308K |
|
24
Vaxcyte
PCVX
$4B
| $282K | 0.12% | +2,468 | New | +$282K |
|
25
Intellia Therapeutics
NTLA
$1.22B
| $268K | 0.11% | +13,020 | New | +$268K |
|